Skip to main content
Figure 2 | BMC Surgery

Figure 2

From: A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT

Figure 2

Flow chart of the CILT study. Derived from an optimal two-stage design for a phase II clinical trial with the following parameters: p 0 = 0.8, p 1 = 0.95, error probability α = 0.05, and error probability β = 0.2. Abbr.: n, number of patients; r, maximum number of responders at which H 0 will not be rejected; H 1, alternative hypothesis.

Back to article page